
BufferPivotal Therapeutics (CSNX:PVO) announced it has filed five international patent applications related to its lead product VASCAZEN. Pivotal President Rachelle MacSweeney said: “The filing of these PCT patent applications is a critical step in Pivotal’s strategy for securing global Intellectual Property rights for VASCAZEN.” Shares of Pivotal closed today down 2.2% to $.225 cents. More… [...]








